Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
HighTide’s First-In-Class Diabetes Contender Numerically Superior To Farxiga Glycemic Control
Dec 03 2025
•
By
Dexter Jie Yan
HighTide Therapeutics’ HTD1801has scored numerical superiority in glycemic control over AstraZeneca’s Farxiga. • Source: Shutterstock
More from Alimentary/Metabolic
More from Clinical Trials